Share: Facebook Twitter LinkedIn
Activity Provided By:

Physicians’ Education Resource®, LLC

Community Practice Connections™: Ophthalmology and Oncology Perspectives on Integrating Novel Bispecific Antibodies Into the Uveal Melanoma Treatment Paradigm

Access Activity

Overview / Abstract:

Target Audience
The target audience for this activity is ocular oncologists, ophthalmologists, and other health care professionals involved in the diagnosis and management of uveal melanoma.

Program Overview
Uveal melanoma is a rare cancer characterized by uncontrolled proliferation of melanocytes within the choroid plexus, ciliary body, or iris. While the average 5-year survival remains at 81%, nearly half of patients eventually develop metastatic disease. Uveal melanoma management depends on early intervention with surgical options to control localized disease; however, there is still no standard of care therapy for metastatic disease, with no significant overall survival improvements associated with chemotherapy, immunotherapy, or targeted therapies. Novel bispecific antibodies in development have shown promise to change this course and offer new options for these patients.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from a live hybrid satellite symposium at the annual meetings of the American Academy of Ophthalmology and American Association of Ophthalmic Oncologists and Pathologists held on October 1, 2022. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects managing patients with uveal melanoma, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Learning Objectives
Upon completion of this activity, participants should be better prepared to:
Determine strategies to optimize the identification of uveal melanoma, including advances in prognostic and genetic evaluation
Explain how genetic biomarkers can be leveraged for risk stratification and how this informs decision-making among patients with uveal melanoma
Describe the efficacy and safety findings from studies that have evaluated bispecific antibodies for the treatment of uveal melanoma
Apply recent evidence to inform clinical decisions given real-world scenarios encountered in the management of uveal melanoma

Expiration

Nov 29, 2023

Discipline(s)

Physician CME

Format

Online

Credits / Hours

1.5

Accreditation

ACCME

Presenters / Authors / Faculty

J. William Harbour, MD
Richard D. Carvajal, MD
Alison H. Skalet, MD, PhD

Sponsors / Supporters / Grant Providers

Immunocore, LLC

Keywords / Search Terms

Relias LLC Relias, Free CME, Uveal Melanoma Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map